An ongoing extension study supports the long-term safety and efficacy of the oral CGRP receptor antagonist atogepant in preventing chronic and episodic migraine. 70% of patients treated with atogepant achieved at least a 50% reduction in monthly migraine days at 13-16 weeks, maintained over 48 weeks. The study, reported at the American Academy of Neurology 2024 annual meeting, included over 500 patients with previous preventive treatment failures. Results showed consistency in efficacy and confirmed the safety profile of atogepant. While the anti-CGRP medications are an important advancement in migraine treatment, their efficacy is generally similar to previous treatments, with a somewhat cleaner safety profile.
Source link
First Long-Term Data on Atogepant for Migraine Prevention
